What is HC Wainwright’s Estimate for UNCY Q2 Earnings?

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Stock analysts at HC Wainwright issued their Q2 2025 earnings estimates for shares of Unicycive Therapeutics in a report issued on Tuesday, May 27th. HC Wainwright analyst S. Ramakanth anticipates that the company will post earnings per share of ($0.08) for the quarter. HC Wainwright currently has a “Strong-Buy” rating and a $9.00 price target on the stock. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.23) per share. HC Wainwright also issued estimates for Unicycive Therapeutics’ Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.03) EPS, FY2025 earnings at ($0.25) EPS, Q1 2026 earnings at $0.27 EPS, Q2 2026 earnings at $0.29 EPS, Q3 2026 earnings at $0.37 EPS, FY2026 earnings at $1.41 EPS, FY2027 earnings at $2.89 EPS, FY2028 earnings at $2.75 EPS and FY2029 earnings at $2.06 EPS.

Separately, Guggenheim began coverage on shares of Unicycive Therapeutics in a report on Monday, April 21st. They set a “buy” rating and a $6.00 price objective on the stock.

Unicycive Therapeutics Stock Up 3.3%

Shares of NASDAQ:UNCY opened at $0.61 on Thursday. Unicycive Therapeutics has a 12 month low of $0.20 and a 12 month high of $0.96. The company’s 50-day moving average price is $0.59 and its two-hundred day moving average price is $0.61. The firm has a market cap of $73.69 million, a P/E ratio of -0.63 and a beta of 2.14.

Unicycive Therapeutics (NASDAQ:UNCY) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.09.

Institutional Investors Weigh In On Unicycive Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Nantahala Capital Management LLC boosted its stake in shares of Unicycive Therapeutics by 268.5% in the 4th quarter. Nantahala Capital Management LLC now owns 10,391,994 shares of the company’s stock valued at $8,253,000 after purchasing an additional 7,571,636 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Unicycive Therapeutics by 30.3% in the 4th quarter. Geode Capital Management LLC now owns 524,487 shares of the company’s stock valued at $417,000 after purchasing an additional 122,089 shares during the last quarter. XTX Topco Ltd boosted its stake in shares of Unicycive Therapeutics by 142.2% in the 4th quarter. XTX Topco Ltd now owns 171,463 shares of the company’s stock valued at $136,000 after purchasing an additional 100,679 shares during the last quarter. Vivo Capital LLC boosted its stake in shares of Unicycive Therapeutics by 123.0% in the 4th quarter. Vivo Capital LLC now owns 9,970,152 shares of the company’s stock valued at $7,918,000 after purchasing an additional 5,500,000 shares during the last quarter. Finally, Octagon Capital Advisors LP boosted its stake in shares of Unicycive Therapeutics by 16.8% in the 4th quarter. Octagon Capital Advisors LP now owns 10,000,000 shares of the company’s stock valued at $7,942,000 after purchasing an additional 1,441,000 shares during the last quarter. Institutional investors own 40.42% of the company’s stock.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.